"One patient in the Mayo Clinic study died from complications related to imetelstat." this was a p1 small trial. Gern has a ways to go. I got out of my short position way to early, I will short it again if it pops to 6
Wow, we another genius here to make intelligent comments. What is the difference between poison and medicine? It is the dose and this has been true for centuries, genius. With infusion treatments, the dose is easily manipulated unlike tablets with 20 or 40 mg doses with nothing in between. It will be adjusted accordingly. What must be considered is the alternative to no treatment with a drug with the efficacy to alter the root cause is death anyhow. See this to take you into science, which is unknown to you and Adam F. sciencebasedmedicine org all medicines are poison
Aspointed out in earlier posts the death was not related to Imelestat as Adam Fartstain yesterday mistakenly reported. He also mistakenly compared Geron's Imelestat to YM BioSciences experimental drug CYT387 in 2011..."when it caused quite a stir with data showing it could reverse anemia in myelofibrosis patients". The only difference is that data from the Mayo clinic has shown that Imelestat has shown that it has reversed it not could. That's a BIG DIFFERENCE!
The cancer patient in question already had pre-existing thrombocytopenia (low platelets) that was given a dose of Imetelstat. He subsequently developed intracranial hemorrhage when his platelet counts dropped even further possibly due to the cancer's progression.
you should short tomorrow on possible small bump , if you wait for $6 ,you might miss big run down ...just get in on short before break down under $5...it was very close below 5 and stay there until CNBC mentioning help float backup to $5.35 and started to drift lower to 5.15 closing time help stay above 5..
There was one death "probably" related to Imetelstat. It was in the setting of a patient with pre-existing thrombocytopenia (low platelets) that was given a dose of Imetelstat and subsequently developed intracranial hemorrhage when his platelet counts dropped even further. Subsequent to this incident, more stringent holding parameters were established so that future patients with significant thrombocytopenia would not be dosed until their platelet counts were increased (as the risk of hemorrhage is too high).
It is indeed a sad occurrence to have a patient die from probable toxicity of a drug, but it is also a valuable learning experience that will make administration safer for all future patients.